Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Clinical trial NCT07502287 · RECRUITING

Trial details

NCT number: NCT07502287
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Neuroblastoma Refractory Neuroblastoma High-Risk Neuroblastoma Ganglioneuroblastoma

Start date: 2026-03-02
Primary completion: 2027-03-14
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.